| Autor: |
Sbitti Y; Department of Medical Oncology, University Military Hospital; Rabat, 10000, Morocco. sbittiyassir@yahoo.fr, Essaidi I, Debbagh A, Kadiri H, Oukabli M, Moussaid Y, Slimani K, Fetohi M, Elkaoui H, Albouzidi A, Mahi M, Ali AA, Ichou M, Errihani H |
| Jazyk: |
angličtina |
| Zdroj: |
World journal of surgical oncology [World J Surg Oncol] 2011 Sep 28; Vol. 9, pp. 112. Date of Electronic Publication: 2011 Sep 28. |
| DOI: |
10.1186/1477-7819-9-112 |
| Abstrakt: |
We report here a 44-year-old Moroccan man with resectable gastric adenocarcinoma with overexpression of human epidermal growth factor receptor 2 (HER2) by immunohistochemistry who was treated with trastuzumab in combination with chemotherapy in perioperative setting. He received 3 cycles of neoadjuvant chemotherapy consisting of trastuzumab, oxaliplatin, and capecitabine. Afterwards, he received total gastrectomy with extended D2 lymphadenectomy without spleno-pancreatectomy. A pathologic complete response was obtained with a combination of trastuzumab and oxaliplatin and capecitabine. He received 3 more cycles of trastuzumab containing regimen postoperatively.We conclude that resectable gastric carcinoma with overexpression of the c-erbB-2 protein should ideally be managed with perioperative combination of trastuzumab with chemotherapy. Further research to evaluate trastuzumab in combination with chemotherapy regimens in the perioperative and adjuvant setting is urgently needed. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
